CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have No Effect on the Anti-Platelet Action of Clopidogrel

被引：0
|
作者：
El-Halabi, Mustapha [1 ]
Malli, Ahmad [1 ]
Mansour, Nabil [1 ]
Ghaith, Ola [1 ]
Saab, Rayan [1 ]
Mahfouz, Rami [1 ]
Alam, Samir [1 ]
Zgheib, Nathalie [1 ]
Sharara, Ala [1 ]
机构：
[1] Amer Univ Beirut, Med Ctr, Beirut, Lebanon
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2012年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
120
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [41] CYP2C19 genotype and the PPIs - focus on rabeprazole
    Lim, PWY
    Goh, KL
    Wong, BCY
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 : S22 - S28
  • [42] Anti-Platelet Therapy in Mild Cerebral Infarction Patients on the Basis of CYP2C19 Metabolizer Status
    Hu Lan
    Tang Ying
    Sheng Xi-Hua
    Li Yi
    CELL TRANSPLANTATION, 2019, 28 (08) : 1039 - 1044
  • [43] CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients
    Yang Jie
    Zhao Hong-Dong
    Tan Jie
    Ding Yun-Long
    Zou Jian-Jun
    PHARMAZIE, 2013, 68 (03): : 183 - 186
  • [44] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Zalloum, Imad
    Hakooz, Nancy
    Arafat, Tawfiq
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (04) : 4195 - 4200
  • [45] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Imad Zalloum
    Nancy Hakooz
    Tawfiq Arafat
    Molecular Biology Reports, 2012, 39 : 4195 - 4200
  • [46] Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays
    Tsantes, Argirios E.
    Ikonomidis, Ignatios
    Papadakis, Ioannis
    Bonovas, Stefanos
    Gialeraki, Argiri
    Kottaridi, Christine
    Kyriakou, Elias
    Kokori, Styliani
    Douramani, Panagiota
    Kopterides, Petros
    Karakitsos, Petros
    Lekakis, John
    Kapsimali, Violetta
    THROMBOSIS RESEARCH, 2013, 132 (02) : E105 - E111
  • [47] Clopidogrel, CYP2C19, and a Black Box
    Ford, Neville F.
    Taubert, Dirk
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03): : 241 - 248
  • [48] The clinical impact of CYP2C19 *2 and *3 polymorphism on Clopidogrel and cost analysis
    Al Meman A
    Khalaf H
    Rasool Seemab
    BMC Genomics, 15 (Suppl 2)
  • [49] Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
    Wang, JH
    Liu, ZQ
    Wang, W
    Chen, XP
    Shu, Y
    He, N
    Zhou, HH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (01) : 42 - 47
  • [50] Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19
    Yu, BN
    Chen, GL
    He, N
    Ouyang, DS
    Chen, XP
    Liu, ZQ
    Zhou, HH
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (10) : 1255 - 1259
12345